Recurrent hemophagocytic lymphohistiocytosis in advanced melanoma treated with two different BRAF/MEK-inhibitor regimens

Melanoma Res. 2023 Apr 1;33(2):159-161. doi: 10.1097/CMR.0000000000000872. Epub 2023 Feb 22.

Authors

Jean-Baptiste Le Goubey¹, Marion Sassier², Ines Nakouri¹, Michel De Pontville¹, Laure Césaire¹, Nicolas Aide³, Diane Kottler¹

Affiliations

¹ Departments of Dermatology.
² Pharmacovigilance.
³ Nuclear Medicine, University Hospital, Caen, France.

PMID: 36815470
DOI: 10.1097/CMR.0000000000000872

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Lymphohistiocytosis, Hemophagocytic*
Melanoma* / drug therapy
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins B-raf / therapeutic use
Skin Neoplasms* / drug therapy

Substances

Proto-Oncogene Proteins B-raf
Protein Kinase Inhibitors
Mitogen-Activated Protein Kinase Kinases
BRAF protein, human